Medicine Information

Livodel

Name: Livodel
Brand: Livodel
Rating: 4.5 (117 reviews)

Syrup1 mg/mlHepatobiliary AgentATC: A05AA02

Generic Name

livodel-1-mg-syrup

Manufacturer

Acme Pharma Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
livodel 1 mg syrup	৳ 35.13	N/A

Description

Overview of the medicine

Livodel 1 mg/ml Syrup contains Ursodeoxycholic Acid (UDCA), a naturally occurring bile acid. It is used to treat various liver and gallbladder disorders by modifying bile composition and protecting liver cells.

Uses & Indications

Dissolution of cholesterol gallstones

Primary Biliary Cholangitis (PBC)

Hepatobiliary disorders associated with Cystic Fibrosis (in children and adolescents)

Cholestatic liver diseases

Dosage

Adults

Dosage varies depending on the indication and patient's weight. For cholesterol gallstone dissolution: 8-10 mg/kg/day, usually divided into 2-3 doses, with the larger dose at bedtime. For PBC: 13-15 mg/kg/day, divided into 2-4 doses.

Elderly

No specific dosage adjustment required; use adult dosage as per body weight and indication.

Renal_impairment

No specific dosage adjustment needed as it is primarily excreted via feces.

How to Take

Take orally, with food, especially the evening dose. Shake the bottle well before use. Measure the dose accurately using the provided measuring device.

Mechanism of Action

Ursodeoxycholic acid (UDCA) acts by increasing the hydrophilicity of the bile acid pool, displacing endogenous toxic bile acids. It also reduces cholesterol synthesis and secretion into bile, facilitating cholesterol gallstone dissolution. UDCA has cytoprotective, anti-apoptotic, and immunomodulatory effects on hepatocytes.

Pharmacokinetics

Onset

Onset of action is variable depending on the indication; gallstone dissolution may take several months.

Excretion

Primarily excreted in feces, a small amount via urine after hepatic metabolism.

Half life

Approximately 3.5 to 5.8 days (due to enterohepatic circulation).

Absorption

Well absorbed from the gastrointestinal tract (about 90%).

Metabolism

Undergoes extensive enterohepatic recirculation; conjugated with glycine and taurine in the liver.

Side Effects

Contraindications

Hypersensitivity to Ursodeoxycholic Acid or any component of the syrup
Acute inflammation of the gallbladder or biliary tract
Occlusion of the biliary tract (common bile duct or cystic duct)
Frequent episodes of biliary colic
Calcified radiopaque gallstones
Impaired contractility of the gallbladder

Drug Interactions

Dapsone

UDCA may reduce the absorption of dapsone.

Ciclosporin

UDCA may increase the absorption of ciclosporin. Monitor ciclosporin levels.

Oral contraceptives, Estrogens, Clofibrate

May increase cholesterol saturation of bile, counteracting the effect of UDCA.

Cholestyramine, Colestipol, Antacids (aluminum hydroxide)

May reduce the absorption of UDCA. Administer UDCA at least 2 hours before or after these agents.

Storage

Store below 30°C. Protect from light and moisture. Do not freeze. Keep the bottle tightly closed.

Overdose

The most common symptom of overdose is diarrhea. In case of overdose, symptomatic treatment and rehydration should be provided. There is no specific antidote.

Pregnancy & Lactation

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are limited well-controlled studies in pregnant women. Use only if clearly needed and the potential benefit outweighs the potential risk. UDCA is excreted into breast milk in very small amounts; generally considered safe during lactation, but caution is advised.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

100 ml syrup200 ml syrup

Shelf Life

24 to 36 months from the date of manufacture when stored as per instructions.

Availability

Pharmacies, hospitals

Approval Status

Approved

Patent Status

Generic available

Clinical Trials

Ursodeoxycholic Acid has been extensively studied in numerous clinical trials for its efficacy in cholesterol gallstone dissolution and the management of various cholestatic liver diseases, including PBC. Ongoing research explores its potential in other liver conditions.

Lab Monitoring

Liver function tests (ALT, AST, ALP, GGT, bilirubin) should be monitored at the start of treatment and every 3 months during the first year, then every 6-12 months.
For gallstone dissolution, check gallstone size via ultrasound every 6-12 months.

Doctor Notes

Confirm diagnosis of cholesterol gallstones or appropriate liver disease before initiating UDCA.
Monitor liver function tests (LFTs) at baseline and periodically.
Advise patients on the importance of adherence, especially for long-term treatments like PBC.
Counsel on potential drug interactions, particularly with bile acid sequestrants and antacids.

Patient Guidelines

Take the medicine exactly as prescribed by your doctor.
Do not stop taking the medicine without consulting your doctor.
Inform your doctor if you experience severe diarrhea or any unusual side effects.
Keep out of reach of children.

Missed Dose Advice

If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one.